EPHA2 and Ewing sarcoma: They demonstrated the role of EphA2 non-canonical pathway activation in the metastatic progression in Ewing’s sarcoma, displaying the more aggressive behavior (in terms of cell proliferation and migration) of cells bearing higher expression levels of p-EphA2Ser897 when compared to those with lower/no p-EphA2Ser897 [13].